DaVita Inc. (DVA)
Here's Why DaVita HealthCare (DVA) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
DaVita HealthCare (DVA) Stock Sinks As Market Gains: Here's Why
DaVita HealthCare (DVA) concluded the recent trading session at $141.84, signifying a -1.36% move from its prior day's close.
Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
DaVita HealthCare (DVA) Rises As Market Takes a Dip: Key Facts
In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $146.71, denoting a +2.99% move from the preceding trading day.
DaVita HealthCare (DVA) Outperforms Broader Market: What You Need to Know
DaVita HealthCare (DVA) reached $137.84 at the closing of the latest trading day, reflecting a +1.26% change compared to its last close.
Here's Why DaVita HealthCare (DVA) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
DaVita: International Expansion And Buybacks Will Boost Returns
International expansion continues with new clinics in Brazil, Ecuador, Chile, and Colombia, supporting long-term growth beyond the US market. DaVita's stock offers a 10% FCF yield, and the share count is decreasing at a fast pace. On top of share buybacks, the company will grow revenues above inflation due to its defensive business model and 35% market share.
Here's Why DaVita HealthCare (DVA) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
DaVita Stock Down Despite Q1 Earnings Beat, Margins Contract
Strength in revenue per treatment and dialysis patient service revenues drives DVA's first-quarter 2025 performance despite a year-over-year decline in normalized non-acquired treatment.
DaVita Inc. (DVA) Q1 2025 Earnings Call Transcript
DaVita Inc. (NYSE:DVA ) Q1 2025 Earnings Conference Call May 12, 2025 5:00 PM ET Company Participants Nic Eliason - Group VP, IR Javier Rodriguez - CEO Joel Ackerman - CFO Conference Call Participants Andrew Mok - Barclays Christian Porter - Bank of America Dean Rosales - Wolfe Research Pito Chickering - Deutsche Bank A.J. Rice - UBS Ryan Langston - TD Cowen Operator Good evening.
DaVita HealthCare (DVA) Q1 Earnings and Revenues Beat Estimates
DaVita HealthCare (DVA) came out with quarterly earnings of $2 per share, beating the Zacks Consensus Estimate of $1.75 per share. This compares to earnings of $2.38 per share a year ago.
